Bexorg: Rethinking CNS drug discovery with whole-human-brain model

Yale spinout Bexorg is developing a platform to test drugs in donated whole human brains that remain molecularly active — an approach the company believes could transform CNS drug discovery.

CNS therapeutics fail at far higher rates than drugs for other organ systems, largely because cultured tissues lack the complexity of living human neurobiology and animal model physiology routinely fails to predict clinical outcomes. Bexorg Inc.’s founders saw an opportunity to address that translational gap by creating a whole-brain model capable of answering questions previously impossible outside the clinic...